DynoSense appointed Pantas Sutardja and Paul Chau to its Board of Directors

– USA, CA – Digital health innovator DynoSense has announced that it has appointed Dr. Pantas Sutardja and Mr. Paul Chau to its board of directors. With extensive experience in technology, finance and global corporate development, the two join DynoSense as the company continues towards regulatory approval and commercialization of its Dyno technology. The Dyno is the world’s first fully integrated multi-function health scanner technology that can capture more than 33 critical health metrics in less than 60 seconds with a single user action. The captured health data is securely and wirelessly uploaded to the company’s cloud computing platform for further analytics and processing, and is then communicated to healthcare professionals.

“DynoSense is a fast growing startup company that aims to be a global leader in the digital healthcare market, and we know that it is our outstanding people who will help get us there,” said Saeed Azimi, chief executive officer of DynoSense. “With their significant and proven experience growing companies and markets, Pantas and Paul will be invaluable additions to our team as we chart an aggressive, yet responsible, path towards our future.”

Dr. Sutardja is an accomplished technologist and entrepreneur. He is co-founder of Marvell Semiconductor Inc. (NASDAQ:MRVL), where he held the positions of board director and chief technology officer for 19 years. During that time, he led Marvell’s technology development from a startup to more than $3 billion per year in revenue and a market capitalization of more than $8 billion, with more than 7,000 employees spanning many countries. He was instrumental in the development of Marvell’s industry leading storage technologies, as well as major core technologies in support of Marvell’s diverse products in communication and complex SOC designs. During his tenure at Marvell, he accumulated more than 300 U.S. patents covering many aspects of semiconductor and storage system technologies. With experience as a public company board member, Sutardja is familiar with the regulatory requirements of developing a company from a startup into a well-managed and rapidly paced growth organization.

Paul Chau is a seasoned executive with more than 18 years of private equity, consulting and technical experience. Currently managing director of international venture capital franchise WI Harper, he oversees venture capital investments, which include those in Payease (acquired by Mozido), Ultriva, Cnano, GCT Semiconductor and Maxic Technology. He is also responsible for the management of the firm’s information technology sector in the United States. Prior to joining WI Harper, Chau served as vice president at Walden International, where he handled investments and the management of existing portfolio companies. He also served as vice president at GIC Special Investment Private Ltd. (Government of Singapore Investment Corporation), where he managed direct private equity and fund investments in the United States. Before joining GIC, Chau was a senior consultant with BARRA, a financial consulting company for pension funds and money management firms. He has served as a member of the board of directors at DivX (NASDAQ:DIVX), USI Insurance Corporation (NASDAQ:USIH), LogicEase (acquired by NYSE: CLGX), and presently holds several directorships in various technology companies.

About DynoSense Corp.

Based in Sunnyvale, Calif., DynoSense Corp. is a digital health innovator founded in 2013. The company’s vision is to be the dominant force behind the digital healthcare revolution. Its mission is to deliver breakthrough products and services for a better life that are integrated, accurate, secure and simple to use.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>